{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-060231","form_type":"8-K","ticker":"ARAY","cik":"0001138723","company_name":"ACCURAY INC","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:28.330532+00:00","generated_at":"2026-06-08T13:30:46.104041+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Accuray Q1 revenue $103.9M (+7.7% YoY), net loss narrows to $3M, reaffirms FY2024 outlook","bullets":["Revenue $103.9M (+7.7% YoY); product rev $53.4M (+19.7%), service rev $50.5M (-2.7%).","GAAP net loss $3.0M ($0.03 diluted loss) vs loss $5.4M ($0.06) prior year; adj EBITDA $6.5M vs $1.9M.","Gross orders $63.7M (book-to-bill 1.2); order backlog $489M, down 9.2% YoY.","Cash $77.4M, down $12.5M from Q4 FY2023; reiterated FY2024 financial guidance.","Operational highlights: FDA clearance and CE mark for VitalHold; China NMPA approval for Tomo C."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-060231","json":"https://secwatch.observer/filing/0000950170-23-060231.json","markdown":"https://secwatch.observer/filing/0000950170-23-060231.md","text":"https://secwatch.observer/filing/0000950170-23-060231.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1138723/000095017023060231/0000950170-23-060231-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1138723/000095017023060231/aray-20231107.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T13:30:46.104041+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a46aba1351576b8e0e531b7eca4265d6a8cf415e","claim":"ACCURAY INC reported first quarter of fiscal 2024 ended September 30, 2023 results: revenue $103.9 million, net income net loss of $3.0 million, or $0.03 per share, EPS $0.03 per share. Guidance reaffirmed.","evidence_excerpt":"Incorporated (NASDAQ: ARAY) today reported financial results for the first quarter of fiscal 2024 ended September 30, 2023. First Quarter Fiscal 2024 Summary • Net revenue of $103.9 million increased 7.7 percent from the same period in the prior fiscal year. Net revenue on a constant currency basis was $102.7 million, which represents a 6.5 percent increase from the","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1138723/000095017023060231/0000950170-23-060231-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter of fiscal 2024 ended September 30, 2023"},{"label":"Revenue","value":"$103.9 million"},{"label":"Net income","value":"net loss of $3.0 million, or $0.03 per share"},{"label":"EPS","value":"$0.03 per share"},{"label":"Guidance","value":"reaffirmed"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}